CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.
Diagnosed with MM per International Myeloma Working Group (IMWG) criteria
Eastern Cooperative Oncology Group Performance Status of 0, or 1, or 2
Resolution of AEs from prior anti-cancer therapy to Grade <=1
Agreement to undergo scheduled assessments and procedures
Inability to comply with protocol-mandated hospitalization and procedures
History of confirmed progressive multifocal leukoencephalopathy
History of other malignancy within 2 years prior to screening
Current or past history of central nervous system (CNS) disease
Hoffmann-La Roche
Lead sponsor